QL1706 (Iparomlimab/Tuvorlimab)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for QL1706 (Iparomlimab/Tuvorlimab), covering 2025-07-25 to 2025-07-25. Get the full timeline:
Most recent: Clinical Trial Update: Iparomlimab/Tuvorlimab (QL1706) and Modified TPF Regimen for Induction Therapy in LANPC [Phase 2]